Adverum Biotechnologies
ADVM
ADVM was delisted on the 8th of December, 2025.
65 hedge funds and large institutions have $67.3M invested in Adverum Biotechnologies in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 10 reducing their positions, and 12 closing their positions.
1,027% more call options, than puts
Call options by funds: $1.48M | Put options by funds: $131K
130% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 10
58% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 12
36% more capital invested
Capital invested by funds: $49.5M → $67.3M (+$17.8M)
12% more funds holding
Funds holding: 58 → 65 (+7)
1.13% more ownership
Funds ownership: 3.14% → 4.27% (+1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
+$7.46M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.63M |
| 3 |
Renaissance Technologies
New York
|
+$2.35M |
| 4 |
Morgan Stanley
New York
|
+$1.9M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.65M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.36M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$2.79M |
| 3 |
VMI
VHCP Management II
New York
|
-$1.02M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$521K |
| 5 |
Schroder Investment Management Group
London,
United Kingdom
|
-$350K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
76
Tower Research Capital (TRC)
New York
| – | -$13K | -362 | Closed |
|
77
UBS Group
Zurich,
Switzerland
| – | -$6K | -179 | Closed |
|
ADVM Hedge Fund Activity: Q4 2017 in Review
65 of the 4,410 institutional investors tracked by Wall St. Rank reported a position in Adverum Biotechnologies (ADVM) for Q4 2017, worth a combined $67.3M — up 36% from $49.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ADVM positions and 12 closed out — a net gain of 7 holders — while 23 added to existing stakes and 10 trimmed.
The largest buyer was Highbridge Capital Management, adding an estimated $7.46M. The largest seller was Fidelity Investments, cutting an estimated $3.36M.
- 65 institutional investors held Adverum Biotechnologies (ADVM) as of Q4 2017, up from 58 in Q3 2017.
- Funds reported $67.3M of Adverum Biotechnologies stock for Q4 2017, up 36% quarter-over-quarter.
- 19 funds opened new Adverum Biotechnologies positions in Q4 2017 and 12 closed out, a net change of +7 holders.
- The largest Adverum Biotechnologies buyer in Q4 2017 was Highbridge Capital Management, an estimated $7.46M added.
- The largest Adverum Biotechnologies seller in Q4 2017 was Fidelity Investments, an estimated $3.36M sold.
Based on aggregated 13F filings for Q4 2017.